The University of Chicago Header Logo

Connection

Justin P. Kline to Immunotherapy

This is a "connection" page, showing publications Justin P. Kline has written about Immunotherapy.
Connection Strength

1.277
  1. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020 02 20; 135(8):523-533.
    View in: PubMed
    Score: 0.468
  2. Mechanisms of Immune Tolerance in Leukemia and Lymphoma. Trends Immunol. 2017 07; 38(7):513-525.
    View in: PubMed
    Score: 0.386
  3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020 12; 8(2).
    View in: PubMed
    Score: 0.123
  4. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015 Oct; 21(10):1209-15.
    View in: PubMed
    Score: 0.086
  5. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
    View in: PubMed
    Score: 0.062
  6. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 2010 Jul; 51(7):1241-50.
    View in: PubMed
    Score: 0.060
  7. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.054
  8. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.